- Push-out Score determined
- After almost seven years in the position
- Praise, thanks and good wishes for Moller
- Thomas Gad taking over temporarily
- Search for a successor
(exechange) — New York, April 27, 2022 — Claus Moller, chief executive of Ymabs, leaves. As announced by Ymabs Therapeutics Inc. in a news release and in a regulatory filing published on Wednesday, April 27, 2022, Claus Moller has left his post as chief executive officer at the commercial-stage biopharmaceutical company, after almost seven years in the role, effective April 22, 2022.
Ymabs will undertake a search for a successor.
Claus Moller’s duties as CEO will be taken over temporarily by Thomas Gad, most recently Founder, Chairman, President and Head of Business Development & Strategy at Ymabs Therapeutics Inc., as Interim Chief Executive Officer.
No reason given
In the announcement, Ymabs did not explicitly explain the reason for the move.
Precise information regarding Claus Moller’s future plans was not immediately available.
Ymabs said: “Dr. Claus Moller has stepped down from his positions as Chief Executive Officer and Board Member effective immediately.”
Ymabs further said: “On April 27, 2022, Y-mAbs Therapeutics Inc. (the “Company”), announced certain executive management changes. Effective April 22, 2022, Dr. Claus Moller stepped down from his positions as Chief Executive Officer and as a member of the Company’s Board of Directors.”
“There were no disagreements with the Company expressed by Dr. Møller on any matter relating the Company’s operations, policies or practices,” Ymabs said.
Share price decline since April 2019
The announcement follows a decline in Y-mAbs Therapeutics Inc.’s share price of 66% since April 2019.
In the position of CEO since 2015
Claus Moller became CEO of the Company in 2015.
Møller has served as the Company’s Chief Executive Officer and has served as a member of the Company’s Board of Directors since June 2015.
Møller was the founder of Azanta A/S, or Azanta, a Danish specialty biopharmaceutical company and its Chief Executive Officer from 2009 to 2015.
In addition, in 1999, Møller co-founded Genmab A/S (“Genmab”), one of the largest European biopharmaceutical companies, where he served as Executive Vice President and Chief Operating Officer until 2008.
Møller has also held previous executive management positions at various biopharmaceutical companies, including Executive Vice President, Chief Medical and Chief Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia.
Møller received his M.D. and Ph.D. degrees from the University of Copenhagen.
Push-out Score determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Claus Moller’s move on a scale of 0 to 10.
exechange reached out to Ymabs and offered the company the opportunity to comment on the score.
Read the full story in the exechange report 18.2022 ($).